Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Clara De Simone, Maria Concetta Fargnoli, Paolo Amerio, Luca Bianchi, Maria Esposito, Federico Pirro, Concetta Potenza, Federica Ricceri, Franco Rongioletti, Luca Stingeni & Francesca Prignano. (2021) Risk of infections in psoriasis: assessment and challenges in daily management. Expert Review of Clinical Immunology 17:11, pages 1211-1220.
Read now
Read now
Cátia Arieira, Francisca Dias de Castro, Tiago Cúrdia Gonçalves, Maria J. Moreira & José Cotter. (2020) Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?. Scandinavian Journal of Gastroenterology 55:8, pages 920-923.
Read now
Read now
Articles from other publishers (43)
Phillip Gu, Shishir Dube, YooJin Lee, Shaohong Yang, Dalin Li, Talin Haritunians, Eric Vasiliauskas, Niru Bonthala, Gaurav Syal, Andres Yarur, David Ziring, Stephan Targan, Shervin Rabizadeh, Gil Y. Melmed, Phillip Fleshner & Dermot P. B. McGovern. (2023) Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn’s Disease (CD). Digestive Diseases and Sciences.
Crossref
Crossref
Koon Jiew Chua, Hua Ling, In Young Hwang, Hui Ling Lee, John C. March, Yung Seng Lee & Matthew Wook Chang. (2022)
An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations in
in vitro
Inflammatory Bowel Disease Models
. ACS Biomaterials Science & Engineering 9:9, pages 5123-5135.
Crossref
Crossref
Marcello Imbrizi, Fernando Magro & Claudio Saddy Rodrigues Coy. (2023) Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years. Pharmaceuticals 16:9, pages 1272.
Crossref
Crossref
Yinfeng Zhang, Tingting Wang, Meng Sun, Yueyue Song, Xinyuan Huang, Shutian Zhang, Jun Yang & Jinfeng Zhang. (2023) Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease. Advanced Healthcare Materials 12:19.
Crossref
Crossref
Ariela K. Holmer, Jiyu Luo, Kirk B. Russ, Sarah Park, Jeong Yun Yang, Furkan Ertem, Jeffrey Dueker, Vu Nguyen, Simon Hong, Cameron Zenger, Jordan E. Axelrad, Anthony Sofia, Jessica C. Petrov, Badr Al-Bawardy, David I. Fudman, Ernesto Llano, Joseph Dailey, Sushrut Jangi, Nidah Khakoo, Oriana M. Damas, Edward L. Barnes, Frank I. Scott, Ryan C. Ungaro & Siddharth Singh. (2023) Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clinical Gastroenterology and Hepatology 21:6, pages 1598-1606.e5.
Crossref
Crossref
Virginia Solitano, Antonio Facciorusso, Tine Jess, Christopher Ma, Cesare Hassan, Alessandro Repici, Vipul Jairath, Alessandro Armuzzi & Siddharth Singh. (2023) Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology 21:4, pages 907-921.e2.
Crossref
Crossref
Siddharth Singh, Brigid S Boland, Tine Jess & Alison A Moore. (2023) Management of inflammatory bowel diseases in older adults. The Lancet Gastroenterology & Hepatology 8:4, pages 368-382.
Crossref
Crossref
Yiwen Guo, Tao Zhang, Ying Xu, Emad Karrar, Minjie Cao, Xiaotian Sun, Ruijie Liu, Ming Chang & Xingguo Wang. (2023) Effects of Medium- and Long-Chain Structured Triacylglycerol on the Therapeutic Efficacy of Vitamin D on Ulcerative Colitis: A Consideration for Efficient Lipid Delivery Systems. Journal of Agricultural and Food Chemistry 71:9, pages 4101-4112.
Crossref
Crossref
Edgar Afecto, Catarina Gomes, Ana Ribeiro, Ana Ponte, João Paulo Correia & Manuela Estevinho. (2023) Not Everything That Ulcerates Is Crohn’s Disease. GE - Portuguese Journal of Gastroenterology 30:3, pages 246-248.
Crossref
Crossref
Meghan Gibson, Shova Subedi, David Barker, Samuel Masur, Meaghan Mallette, Archana Lingannan, Aldo Alejandro Recinos Soto, Dyadin Esharif, Sarah Maxwell, Muhammad Safwan Riaz, Michael Ian Herzlinger, Linda Shalon, Carolina Cerezo, Vania Kasper, Albert Ross, Neal S. Leleiko & Jason M. Shapiro. (2023) Safety and Durability of Accelerated Infliximab Dosing Strategies in Pediatric IBD: A Single Center, Retrospective Study. Journal of Pediatric Gastroenterology & Nutrition Publish Ahead of Print.
Crossref
Crossref
Sen Lin, Haosen Zhao, Chang Xu, Peng Zhang, Xifan Mei & Dingwen Jiang. (2023) Sulfasalazine-loaded nanoparticles for efficient inflammatory bowel disease therapy via ROS-scavenging strategy. Materials & Design 225, pages 111465.
Crossref
Crossref
Lucas Guillo, Benoit Flachaire, Jérôme Avouac, Catherine Dong, Maria Nachury, Guillaume Bouguen, Anthony Buisson, Ludovic Caillo, Mathurin Fumery, Cyrielle Gilletta, Xavier Hébuterne, Pierre Lafforgue, David Laharie, Emmanuel Mahé, Hubert Marotte, Stéphane Nancey, Sébastien Ottaviani, Jean-Hugues Salmon, Guillaume Savoye, Mélanie Serrero, Mathieu Uzzan, Manuelle Viguier, Christophe Richez, Laurent Peyrin-Biroulet, Philipe Seksik, Thao Pham, Philippe Ah-Soune, Nadia Arab, Laurent Beaugerie, Loïs Bolko, Joelle Bonnet, Yoram Bouhnik, Anne Bourrier, Franck Brazier, Franck Carbonnel, Maeva Charkaoui, Isabelle Charlot-Lambrecht, Antoine Chupin, Alice Combier, Marion Couderc, Fabienne Coury-Lucas, Ariadne Desjeux, Catherine Dong, Nicolas Duveau, Anne Grasland, Jean-Charles Grimaud, Xavier Guennoc, Cécilia Landman, Isabelle Nion-Larmurier, Catherien Leberre, Romain Leenhardt, Aude Le Goffic, Henri Montaudie, Jacques Morel, Thierry Passeron, Jeanne-Marie Perotin Collard, Elodie Poisnel, Vincent Pradel, Martin Soubrier, Harry Sokol, Eric Toussirot, Caroline Trang, My-Linh Trans Minh, Sophie Trijau, Frank Verhoeven, Stéphanie Viennot & Daniel Wendling. (2023) Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study. Digestive and Liver Disease 55:1, pages 61-68.
Crossref
Crossref
Maria Antonietta Barbieri, Anna Viola, Giuseppe Cicala, Edoardo Spina & Walter Fries. (2022) Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project. Biomedicines 10:12, pages 3280.
Crossref
Crossref
Adam S. Faye, Ariela K. Holmer & Jordan E. Axelrad. (2022) Cancer in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 51:3, pages 649-666.
Crossref
Crossref
Xingyu Ma, Qianqian Di, Xiaoli Li, Xibao Zhao, Ruihan Zhang, Yue Xiao, Xunwei Li, Han Wu, Haimei Tang, Jiazheng Quan, Zherui Wu, Weilie Xiao & Weilin Chen. (2022) Munronoid I Ameliorates DSS-Induced Mouse Colitis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Via Modulation of NLRP3. Frontiers in Immunology 13.
Crossref
Crossref
Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori, Koichi Nakajima, Tetsuya Ishida, Yoh Ishiguro, Kazunari Kanke, Kiyonori Kobayashi, Fumihito Hirai, Kenji Watanabe, Hidehiro Mizusawa, Shuji Kishida, Yoshiharu Miura, Akira Ohta, Toshifumi Kajioka, Toshifumi Hibi, Satoshi Motoya, Atsuo Maemoto, Mikihiro Fujiya, Toshifumi Ashida, Mitsuru Goto, Takayuki Matsumoto, Yasuo Suzuki, Yukihiro Hamahata, Tomoo Nakagawa, Naoya Kato, Jun Kato, Yutaka Endo, Ryoichi Suzuki, Koichiro Matsuda, Naoki Ohmiya, Shinji Katsushima, Shuhei Hosomi, Ken-ichi Tarumi, Chiyuki Watanabe, Mitsuru Saito, Yuichiro Yokoyama, Tomoki Inaba, Yasuhisa Sakata, Hitoshi Hongo, Tomoyoshi Shibuya, Kazuhiko Kawakami, Yoichi Kakuta, Atsushi Irisawa, Naoki Yoshimura, Katsuyuki Fukuda, Takayuki Shirai, Hitoshi Ichikawa, Junko Nagata, Takayoshi Suzuki, Kaoru Yokoyama, Takashi Tomidokoro, Yuichiro Kojima, Masahiro Yamada, Hideko Yamamoto, Takayuki Yamamoto, Noriyuki Horiki, Hirozumi Obata, Satoko Inoue, Shinji Tanaka, Tatsuya Toyokawa, Masaki Kunihiro, Takashi Hisabe, Shinichi Ogata, Fuminao Takeshima, Kayoko Matsushima, Nobuyuki Matsuhashi, Hirotake Sakuraba, Masahiro Iwabuchi, Akihiko Tsuchiya, Kan Uchiyama, Takanori Kanai, Masanao Nakamura, Tadashi Yokoyama, Nobuyuki Hida, Keiichi Mitsuyama, Taro Osada, Sakiko Hiraoka, Tomoyuki Tsuzuki, Takashige Masuo, Ryota Hokari, Taku Kobayashi, Masayuki Saruta, Masao Araki, Hiroshi Araki, Masahito Shimizu, Masakazu Kikuchi, Takahiro Nishikawa, Hidetoshi Takedatsu, Kunihiko Aoyagi, Toshiaki Ochiai, Nobuo Toda, Yuji Mizokami, Masakazu Nagahori, Kazuhiro Matsueda, Hitoshi Kino, Akira Kanamori, Tsunehiro Suzuki, Toshiharu Sakurai, Masatoshi Kudo, Atsuo Kitano, Tadakazu Hisamatsu, Shinji Kumagai, Tomoyuki Ninomiya, Kenichiro Mori, Shun-ichi Yoshida & Mitsuhide Goto. (2022) AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology & Hepatology 7:7, pages 648-657.
Crossref
Crossref
Siddharth Singh, Herbert C. Heien, Lindsey Sangaralingham, Nilay D. Shah & William J. Sandborn. (2021) Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences 67:6, pages 2510-2516.
Crossref
Crossref
Siddharth Singh & Parambir S. Dulai. 2022. Yamada's Textbook of Gastroenterology. Yamada's Textbook of Gastroenterology
1248
1293
.
Beth-Ann Norton, Anne Sullivan, Jennifer Senior, Ninfa Candela, Mary Jason & Katherine Weyant. (2022) Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners. The Journal for Nurse Practitioners 18:4, pages 438-445.
Crossref
Crossref
Markus Ries, Brice Moulari, Maryam A. Shetab Boushehri, Mohamed Ehab Ali, Daniel Molnar, Arnaud Béduneau, Yann Pellequer & Alf Lamprecht. (2022) Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting. Pharmaceutics 14:2, pages 352.
Crossref
Crossref
Siddharth Singh, Herbert C. Heien, Jeph Herrin, Parambir S. Dulai, Lindsey Sangaralingham, Nilay D. Shah & William J. Sandborn. (2022) Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 20:2, pages e74-e88.
Crossref
Crossref
瑞芳 胡. (2022) Clinical Research Progress of Infliximab Combined with Azathioprine in the Treatment of Inflammatory Bowel Disease. Advances in Clinical Medicine 12:12, pages 10987-10993.
Crossref
Crossref
Mahmoud Mosli, Turki Alameel & Ala I. Sharara. (2022) Mucosal Healing in Crohn’s Disease: Bull’s Eye or Bust? The “Relative” Con Position. Inflammatory Intestinal Diseases 7:1, pages 42-49.
Crossref
Crossref
Kaitlyn Anderson, Kerry Moss, Brendan Campbell, Douglas Moote, Kari Kakazu & Jeffrey S. Hyams. (2022) Follicular Dendritic Cell Sarcoma in a Patient With Adolescent-Onset Crohn’s Disease Exposed to Multiple Immunomodulator and Biologic Therapies. JPGN Reports 3:3, pages e231.
Crossref
Crossref
Pei Liu, Haoyue Wang, Jiejie Hu, Xiaobin Zhai & Zhaoming Ge. (2021) Analysis on the Clinical Effect of High-Dose Glucocorticoids Combined with Immunosuppressants on Patients with Myasthenia Gravis Undergoing Video-Assisted Thoracoscopic Surgery. BioMed Research International 2021, pages 1-6.
Crossref
Crossref
Joseph Meserve & Siddharth Singh. (2021) Editorial: risk of pneumonia in IBD—reading between the lines!. Alimentary Pharmacology & Therapeutics 54:11-12, pages 1490-1491.
Crossref
Crossref
Adam S. CheifetzMaria T. AbreuWaqqas AfifRaymond K. CrossMarla C. DubinskyEdward V. LoftusMark T. OstermanAriana SaroufimCorey A. SiegelAndres J. YarurGil Y. MelmedKonstantinos Papamichael. (2021) A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology 116:10, pages 2014-2025.
Crossref
Crossref
Jo Taylor. (2021) Patient access to biological medications for ulcerative colitis. Gastrointestinal Nursing 19:7, pages 32-38.
Crossref
Crossref
Jianyi Dong, Yuanyuan Chen, Fang Yang, Weidong Zhang, Kun Wei, Yongjian Xiong, Liang Wang, Zijuan Zhou, Changyi Li, Jingyu Wang & Dapeng Chen. (2021) Naringin Exerts Therapeutic Effects on Mice Colitis: A Study Based on Transcriptomics Combined With Functional Experiments. Frontiers in Pharmacology 12.
Crossref
Crossref
Siddharth SinghHerbert C. HeienLindsey SangaralinghamNilay D. ShahWilliam J. Sandborn. (2021) Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology 12:7, pages e00380.
Crossref
Crossref
Michael J. Stewart, Talat Bessissow, James Gregor, Maureen Hazel, Tracy S. H. In, Kinda Karra, Dorota Dajnowiec, Martin Williamson & Bernie Sattin. (2021) Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis. Advances in Therapy 38:7, pages 4115-4129.
Crossref
Crossref
Siddharth Singh, Deborah Proctor, Frank I. Scott, Yngve Falck-Ytter & Joseph D. Feuerstein. (2021) AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology 160:7, pages 2512-2556.e9.
Crossref
Crossref
Zhihua Geng & Qing Geng. (2021) Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis. Frontiers in Surgery 8.
Crossref
Crossref
Nabeel Khan, Tyler Pernes, Alexandra Weiss, Chinmay Trivedi, Manthankumar Patel, Dawei Xie & Yu-Xiao Yang. (2021) Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study. Advances in Therapy 38:5, pages 2586-2598.
Crossref
Crossref
Han-Yu Lei, Ying-He Ding, Kai Nie, Yin-Miao Dong, Jia-Hao Xu, Meng-Ling Yang, Meng-Qi Liu, Le Wei, MI Nasser, Lin-Yong Xu, Ping Zhu & Ming-Yi Zhao. (2021) Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver. Biomedicine & Pharmacotherapy 133, pages 111064.
Crossref
Crossref
Giuseppe Biscaglia, Mariano Piazzolla, Francesco Cocomazzi, Gennaro Melchionda, Angelo De Cata, Fabrizio Bossa, Orazio Palmieri & Angelo Andriulli. (2020) Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. European Journal of Gastroenterology & Hepatology 32:12, pages 1579-1582.
Crossref
Crossref
Corey A Siegel, Britt Christensen, Asher Kornbluth, Joel R Rosh, Michael D Kappelman, Ryan C Ungaro, Douglas Forsyth Johnson, Scott Chapman, David A Wohl & Gerassimos J Mantzaris. (2020) Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19. Journal of Crohn's and Colitis 14:Supplement_3, pages S769-S773.
Crossref
Crossref
M E de Jong, L J T Smits, B van Ruijven, N den Broeder, M G V M Russel, T E H Römkens, R L West, J M Jansen & F Hoentjen. (2020) Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis 14:7, pages 888-895.
Crossref
Crossref
Markus F Neurath. (2020) COVID-19 and immunomodulation in IBD. Gut 69:7, pages 1335-1342.
Crossref
Crossref
Nghia H. Nguyen, Siddharth Singh & William J. Sandborn. (2020) Positioning Therapies in the Management of Crohn’s Disease. Clinical Gastroenterology and Hepatology 18:6, pages 1268-1279.
Crossref
Crossref
Siddharth Singh, Jessica R. Allegretti, Shazia Mehmood Siddique & Jonathan P. Terdiman. (2020) AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 158:5, pages 1465-1496.e17.
Crossref
Crossref
Ariela K. Holmer, Robert Battat, Parambir S. Dulai, Niels Vande Casteele, Nghia Nguyen, Anjali Jain, Ara Miralles, Jennifer Neill, Helen Le, Siddharth Singh, Jesus Rivera-Nieves, William J. Sandborn & Brigid S. Boland. (2020) Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease. Therapeutic Advances in Gastroenterology 13, pages 175628482097121.
Crossref
Crossref
Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori, Kouichi Nakajima, Tetsuya Ishida, Yoh Ishiguro, Kazunari Kanke, Kiyonori Kobayashi, Fumihito Hirai, Kenji Watanabe, Hidehiro Mizusawa, Shuji Kishida, Yoshiharu Miura, Akira Ohta, Toshifumi Kajioka & Toshifumi Hibi. (2021) AJM300 (Carotegrast Methyl), an Oral Antagonist of α4-Integrin, as Induction Therapy for Patients with Moderately Active Ulcerative Colitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. SSRN Electronic Journal.
Crossref
Crossref